Upjohn Gets Go-Ahead to Market Cholesterol Reducing Tablets
KALAMAZOO, Mich. (AP) _ The Upjohn Co. has been given approval to market a tablet form of its cholesterol-lowering medication, the company said Friday.
Colestid Tablets will be available by prescription in December, the company said in a release. The tablets contain micronized cholestipol hydrochloride, the same active ingredient in Upjohn’s Colestid Granules.
The medication is used in conjunction with a low-cholesterol diet to reduce high total cholesterol and low-density lipoprotein, generally regarded as the bad form of cholesterol.
″Studies have shown that approximately 52 million Americans have high blood cholesterol and 13 million can’t reduce it with diet alone,″ said Jack J. Jackson, corporate senior vice president for U.S. and Canadian Pharmaceutical Operations.
The tablet form is an alternative to the granules, which need to be mixed with water or juice, Jackson said.
Colestid works by attaching itself to certain cholesterol-containing molecules in the gastrointestinal tract and carrying them out of the body. It does not circulate through the blood stream.